CoreValve Evolut-R TAVR (29mm) via Percutaneous Femoral Access – Dec 2015

An 84 year-old male presented with progressive shortness of breath and chest discomfort – NYHA class II, with a history of hypertension, I vessel CAD, COPD, TIA, s/p BAV on 10/2/15, s/p rt. radical nephrectomy, stage III CKD, and h/o CA prostrate. TTE revealed severe AS, peak/mean aortic gradient = 85/56 mmHg, AVA = 0.8 sq cm, aortic peak velocity = 4.6 m/sec and LVEF 77%. CT angio showed minimum diameters of 0.7 x 0.8 cm for right and 0.7 x 0.7 cm for left common femoral arteries and aortic annulus of 2.6 X 2.2 cm (average 2.4 cm). The STS risk mortality is 9.5 % and the Logistic Euroscore mortality is 20.27 %. Patient was determined to be very high risk for surgical AVR due to advanced age, high right diaphragm, renal insufficiency, COPD, and obesity. Patient is now planned for CoreValve Evolut-R TAVR (29mm) via percutaneous femoral access under conscious sedation.



Leave a Reply

Your email address will not be published.*

Warning: Invalid argument supplied for foreach() in /home/ on line 1080

Yes, I would like to receive emails from Mount Sinai Hospital. Sign me up!

By submitting this form, you are consenting to receive marketing emails from: Mount Sinai Hospital, One Gustave L. Levy Place, Box, New York, NY, 10029, You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact